Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

SHA:688319 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	184.32	224.16	362.07	269.23	254.37	103.98
Trading Asset Securities	17.6	17.5	0	90	200	10
Cash & Short-Term Investments	201.92	241.66	362.07	359.23	454.37	113.98
Cash Growth	-31.72%	-33.26%	0.79%	-20.94%	298.63%	19.21%
Accounts Receivable	617.27	570.35	491.55	491.69	342.52	192.26
Other Receivables	2.34	1	1.1	3.78	1.1	0.81
Receivables	619.62	571.35	492.65	495.48	343.62	193.06
Inventory	76.04	85.68	72.12	78.52	74.5	46
Prepaid Expenses	1.21	-	0	0	0.06	-
Other Current Assets	9.42	9.45	4.35	2.66	2.42	9.71
Total Current Assets	908.2	908.14	931.19	935.89	874.98	362.76
Property, Plant & Equipment	595.35	572.3	425.87	378.35	259.27	240.39
Other Intangible Assets	17.58	16.33	16.82	17.51	13.78	12.22
Long-Term Deferred Tax Assets	18.21	18.21	14.07	9.56	7.11	-
Long-Term Deferred Charges	296.2	291.5	195.76	132.31	34.93	19.74
Other Long-Term Assets	0.69	0.56	28.89	5.24	21.82	6.15
Total Assets	1,836	1,807	1,613	1,479	1,212	641.26
Accounts Payable	86.43	86.29	40.06	80.68	34.28	33.08
Accrued Expenses	369.99	368.06	346.13	321.65	251.98	167.58
Short-Term Debt	20	24.2	24.2	85	35	25
Current Portion of Long-Term Debt	65.95	87.42	31.69	10	-	-
Current Income Taxes Payable	1.45	9.44	3.74	9.46	4.03	-
Current Unearned Revenue	0.62	0.51	3.62	6.71	7.5	2.56
Other Current Liabilities	18.33	19.67	26.79	11.73	8.88	11.6
Total Current Liabilities	562.78	595.59	476.22	525.23	341.66	239.83
Long-Term Debt	304.24	249.53	177.29	29.99	-	-
Long-Term Leases	7.34	0.64	4.43	9.04	3.25	2.49
Long-Term Unearned Revenue	23.25	24.79	19.98	20.11	18.67	19.13
Long-Term Deferred Tax Liabilities	2.46	2.46	2.72	2.56	2.3	-
Other Long-Term Liabilities	1.74	0.53	1.21	0.09	1.33	2.84
Total Liabilities	901.81	873.54	681.84	587.02	367.22	264.29
Common Stock	405.93	405.93	406.16	405.27	405.27	364.74
Additional Paid-In Capital	593.69	606	605.75	580.95	570.56	251.37
Retained Earnings	-68.5	-81.7	-87.04	-104.59	-131.17	-239.13
Treasury Stock	-5.56	-5.56	-7.96	-	-	-
Total Common Equity	925.56	924.68	916.91	881.63	844.66	376.97
Minority Interest	8.86	8.82	13.86	10.22	-	-
Shareholders' Equity	934.42	933.5	930.77	891.85	844.66	376.97
Total Liabilities & Equity	1,836	1,807	1,613	1,479	1,212	641.26
Total Debt	397.54	361.79	237.61	134.03	38.25	27.49
Net Cash (Debt)	-195.61	-120.13	124.47	225.2	416.11	86.49
Net Cash Growth	-	-	-44.73%	-45.88%	381.08%	0.86%
Net Cash Per Share	-0.48	-0.30	0.31	0.56	1.08	0.24
Filing Date Shares Outstanding	405.93	405.93	406.16	405.27	405.27	364.74
Total Common Shares Outstanding	405.93	405.93	406.16	405.27	405.27	364.74
Working Capital	345.42	312.55	454.97	410.67	533.31	122.93
Book Value Per Share	2.28	2.28	2.26	2.18	2.08	1.03
Tangible Book Value	907.98	908.35	900.08	864.11	830.88	364.75
Tangible Book Value Per Share	2.24	2.24	2.22	2.13	2.05	1.00
Buildings	224.69	224.69	96.22	103.17	103.17	-
Machinery	340.97	318.26	299.39	261.88	245.29	-
Construction In Progress	217.5	211.27	181.35	135.49	11.63	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.